Oncotarget

Reviews:

Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma

Eva González-Barca _, Mónica Coronado, Alejandro Martín, Carlos Montalbán, Santiago Montes-Moreno, Carlos Panizo, Guillermo Rodríguez, Juan Manuel Sancho, Andrés López-Hernández and on behalf of the Spanish Lymphoma Group (GELTAMO)

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:32383-32399. https://doi.org/10.18632/oncotarget.25892

Metrics: PDF 2591 views  |   HTML 5894 views  |   ?  


Abstract

Eva González-Barca1, Mónica Coronado2, Alejandro Martín3, Carlos Montalbán4, Santiago Montes-Moreno5, Carlos Panizo6, Guillermo Rodríguez7, Juan Manuel Sancho8, Andrés López-Hernández9 and on behalf of the Spanish Lymphoma Group (GELTAMO)

1Department of Hematology, Institut Català d’ Oncologia and IDIBELL, L’ Hospitalet de Llobregat, Barcelona, Spain

2Department of Nuclear Medicine, Hospital Universitario La Paz, Madrid, Spain

3Department of Hematology, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain

4Department of Hematology, MD Anderson Cancer Center, Madrid, Spain

5Department of Pathology and Translational Hematopathology Lab, Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain

6Department of Hematology, Clínica Universidad de Navarra and Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain

7Department of Hematology, Hospital Universitario Virgen de la Macarena, Sevilla, Spain

8Department of Hematology, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

9Department of Hematology, Hospital Universitario Vall d’Hebron, Barcelona, Spain

Correspondence to:

Eva González-Barca, email: [email protected]

Keywords: guidelines; DLBCL; risk assessment; treatment; DLBCL entities

Received: March 21, 2018     Accepted: July 23, 2018     Published: August 17, 2018

ABSTRACT

Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 30% of non-Hodgkin lymphoma (NHL) cases in adult series. DLBCL is characterized by marked clinical and biological heterogeneity, encompassing up to 16 distinct clinicopathological entities. While current treatments are effective in 60% to 70% of patients, those who are resistant to treatment continue to die from this disease.

An expert panel performed a systematic review of all data on the diagnosis, prognosis, and treatment of DLBCL published in PubMed, EMBASE and MEDLINE up to December 2017. Recommendations were classified in accordance with the Grading of Recommendations Assessment Development and Evaluation (GRADE) framework, and the proposed recommendations incorporated into practical algorithms. Initial discussions between experts began in March 2016, and a final consensus was reached in November 2017. The final document was reviewed by all authors in February 2018 and by the Scientific Committee of the Spanish Lymphoma Group GELTAMO.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25892